The COVID-19 pandemic, caused by SARS-CoV-2, has severely impacted global public health and the economy. While effective vaccination programmes, lockdown and distancing measures have helped to decelerate the spread of the virus across the globe, the constant mutation of the virus leading new variants is alarming. A possible alternative approach to combat the virus is to develop an epitope-based peptide vaccine, which is conserved across multiple variants of the virus. Although several studies have predicted CD8+ and CD4+ epitopes of SARS-CoV-2, the bases of focus have primarily been MHC-peptide binding and epitope conservancy, which are not enough to support epitope viability. Here, we sought to identify promising CD8+ and CD4+ epitopes based on a combination of 6 different strategies. Using bioinformatics tools, we screened complete SARS-CoV-2 spike, envelope, membrane, nsp2, nsp12 and nsp13 protein sequences to predict possible epitopes before filtering them based on MHC-peptide binding, antigen processing and transport, immunogenicity, conservancy, and cross-reactivity. We identified 18 promising CD8+ epitopes and 4 promising CD4+ epitopes providing a cumulative global population coverage of 94.53%. These peptides are predicted to be immunogenic, conserved across multiple variants including the delta and omicron mutants, and are not cross reactive with human proteins. The findings of our study provide insights on SARS-CoV-2 T-cell epitopes and together with the known B-cell epitopes, potential multi-epitope-based peptide vaccine constructs for preclinical and clinical studies against Covid-19 and a way forward to serve as a novel platform for future vaccine design.